We found that IL-18 could up-regulate c-myc and bcl-2, and down-regulate TP53 and bax expression, thereby promoting lymphoma cell proliferation, inhibiting lymphoma cell apoptosis and reducing the anti-tumor effect of dexamethasone. Here, MYC is linked to neoplasm.